跳到正文
登录

公司

Actinium Pharmaceuticals

打开结构图

Actinium Pharmaceuticals 的结构

Actinium Pharmaceuticals

公司

10 个关联
上游供应与依赖
自有产品与技术
下游客户
同行竞争与合作
约束监管与敞口
关系出现时间2026
Actinium Pharmaceuticals公司 · 10 个关联
第 1 层

上游供应与依赖5

下游客户1

同行竞争与合作1

自有产品与技术1

约束监管与敞口2

在关系网络中的位置

第 2180 位,共 118934 个前 2%本周上升 5605 位

10 条直接关系

所在群组共 451 个紧密关联的对象,核心是

本周新增关系

按有证据的公开关系计算,每天更新。

关系

箭头表示关系方向,可按业务类别筛选。

  • Actinium Pharmaceuticals合作 →National Cancer Institute
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-10-17 05:00
      Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI)
      查看来源
    • 公司披露PR Newswire news releases2026-10-16 19:30
      Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI)
      查看来源
    • 公司披露PR Newswire news releases2026-10-16 19:30
      with additional development ongoing through a CRADA with the NCI.
      查看来源
    • 公司披露PR Newswire news releases2026-10-15 19:30
      Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI)
      查看来源
  • Sean Maenpaa属于 →Actinium Pharmaceuticals
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-10-16 19:30
      announced the appointment of Sean Maenpaa as Senior Vice President, Business Development
      查看来源
  • 事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-10-17 05:00
      risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC")
      查看来源
  • 事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-10-17 05:00
      the market demand for and acceptance of Actinium's products and services
      查看来源
  • Actinium Pharmaceuticals使用 →HER3
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-17 20:00
      Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400
      查看来源
  • Actinium Pharmaceuticals使用 →Iomab-ACT
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-17 20:00
      Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.
      查看来源
  • 事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-17 20:00
      Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.
      查看来源
  • Actinium Pharmaceuticals使用 →Actimab-A
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-17 20:00
      Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.
      查看来源

显示第 1 至 8 条,共 10 条

结论

结合来源阅读结论,展开条目查看证据。

事实证据 3
监管敞口FDA

These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including risks and uncertainties associated with the conduct, timing and r…

PR Newswire news releases · 2026-11-17 20:00

查看证据
  • 公司披露PR Newswire news releases2026-11-17 20:00
    These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including risks and uncertainties associated with the conduct, timing and r…
    查看来源
  • 公司披露PR Newswire news releases2026-10-17 05:00
    actions by the FDA and other governmental agencies
    查看来源
  • 公司披露PR Newswire news releases2026-10-16 19:30
    risks and uncertainties associated with the Company's ability to retain key personnel, the Company's ability to identify, negotiate and complete business development, partnering, licensing or other strategic transactions on favorable terms or at all, estimates of potential marke…
    查看来源
事实证据 1

Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.

PR Newswire news releases · 2026-11-17 20:00

查看证据
  • 公司披露PR Newswire news releases2026-11-17 20:00
    Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.
    查看来源
事实证据 2
使用ATNM-400

Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400

PR Newswire news releases · 2026-11-17 20:00

查看证据
  • 公司披露PR Newswire news releases2026-11-17 20:00
    Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400
    查看来源
  • 公司披露PR Newswire news releases2026-11-17 20:00
    Actinium will present preclinical data demonstrating ATNM-400's activity across therapy-resistant breast cancer models, further supporting its potential across multiple solid tumor indications.
    查看来源
事实证据 1
expected operations funding through2027

Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.

PR Newswire news releases · 2026-11-17 20:00

查看证据
  • 公司披露PR Newswire news releases2026-11-17 20:00
    Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.
    查看来源
事实证据 1
cash and cash equivalents28.7 million

Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.

PR Newswire news releases · 2026-11-17 20:00

查看证据
  • 公司披露PR Newswire news releases2026-11-17 20:00
    Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.
    查看来源
事实证据 1
使用Iomab-ACT

Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.

PR Newswire news releases · 2026-11-17 20:00

查看证据
  • 公司披露PR Newswire news releases2026-11-17 20:00
    Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.
    查看来源

显示第 1 至 6 条,共 18 条

市场与估值

估值数据需要 Pro 或 Research。

升级到 Pro 解锁

推荐一个值得监测的页面

这家公司有哪些页面值得盯着,比如价格、更新日志、条款或招聘页?推荐给我们。每条推荐都有人看;收录后,这个页面会为所有读者一起监测,并且只有连续两次抓取一致才算一次变化。

登录后推荐页面

暂无: 公司信号 · 财务数据 · 披露文件 · 据点 · 业绩指引